Clinical trial
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of IxCell hUC-MSC-S in Patients With Ischemic Stroke in the Recovery Phase
NCT07197606 is registered in ClinicalTrials.gov with Shanghai IxCell Biotechnology Co., LTD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of IxCell hUC-MSC-S in Patients With Ischemic Stroke in the Recovery Phase
- Lead sponsor
- Shanghai IxCell Biotechnology Co., LTD
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- October 1, 2025
- Completion date
- December 31, 2027
- Enrollment
- 86 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.